Growing evidence indicates that microRNAs have a significant role in tumor development and may constitute robust biomarkers for cancer diagnosis and prognosis. In this study, we evaluated the clinical and functional relevance of microRNA-122 (miR-122) expression in human hepatocellular carcinoma (HCC). We report that miR-122 is specifically repressed in a subset of primary tumors that are characterized by poor prognosis. We further show that the loss of miR-122 expression in tumor cells segregates with specific gene expression profiles linked to cancer progression, namely the suppression of hepatic phenotype and the acquisition of invasive properties. We identify liver-enriched transcription factors as central regulatory molecules in the gene networks associated with loss of miR-122, and provide evidence suggesting that miR-122 is under the transcriptional control of HNF1A, HNF3A and HNF3B. We further show that loss of miR-122 results in an increase of cell migration and invasion and that restoration of miR-122 reverses this phenotype. In conclusion, miR-122 is a marker of hepatocyte-specific differentiation and an important determinant in the control of cell migration and invasion. From a clinical point of view, our study emphasizes miR-122 as a diagnostic and prognostic marker for HCC progression.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of death from cancer worldwide, accounting for at least 600 000 deaths annually (Parkin et al., 2005) . The most prominent etiologies of HCC include chronic viral hepatitis B and C (HBV, HCV), alcoholic or nonalcoholic steatohepatitis, and aflatoxin intoxication (Thorgeirsson and Grisham, 2002; ElSerag, 2004) . Although recent advances in functional genomics provide an increasingly comprehensive portrayal of hepatocarcinogenesis Villanueva et al., 2007) , the molecular pathogenesis of HCC remains poorly understood. Indeed, the clinical heterogeneity of HCC and the lack of good diagnostic markers and treatment strategies have rendered the disease a major challenge.
MicroRNAs (miRNAs) belong to an abundant family of endogenous, short and noncoding RNAs that are believed to be key post-transcriptional regulators of gene activity. It has been widely shown that miRNAs have an important role in the control of numerous biological processes, such as development, differentiation, proliferation and apoptosis (Ambros, 2004) . Therefore, it is not surprising that miRNAs have been implicated in cancer as well. An altered miRNA expression was observed in a large variety of neoplasms (Lu et al., 2005) , including HCC (Murakami et al., 2006; Braconi and Patel, 2008; Budhu et al., 2008; Ladeiro et al., 2008; Li et al., 2008; Wong et al., 2008) . The significance of miRNAs in cancer onset and progression has been supported by the experimental demonstrations of their oncogenic and tumor-suppressive properties (Esquela-Kerscher and Slack, 2006) . In addition, miR-NA genes have been found to be frequently located in cancer-associated genomic regions, such as fragile sites, minimal regions of loss of heterozygosity and minimal regions of amplification (Calin et al., 2004) . is the most abundant miRNA in the liver accounting for approximately 70% of the total miRNA population (Lagos-Quintana et al., 2002; Chang et al., 2004) . Although miR-122 has been described as a liver-specific miRNA, slight expression has been also reported in the heart (Tang et al., 2007) . Several studies have emphasized the importance of miR-122 in liver homeostasis. In vivo, miR-122 has notably been implicated in fatty acid and cholesterol metabolism and HCV infection (Jopling et al., 2005; Krutzfeldt et al., 2005; Esau et al., 2006; Chang et al., 2008; Cheung et al., 2008; Elmen et al., 2008; Henke et al., 2008) . Expression of miR-122 has been found to be repressed in HCC (Kutay et al., 2006; Murakami et al., 2006; Gramantieri et al., 2007; Braconi and Patel, 2008; Budhu et al., 2008; Girard et al., 2008; Ladeiro et al., 2008; Lin et al., 2008) as well as in nonalcoholic steatohepatitis (Cheung et al., 2008) . Recent works suggest that miR-122 deregulation is associated either with specific clinical risk factors (HBV, HCV) or HCC metastasis (Braconi and Patel, 2008; Budhu et al., 2008; Girard et al., 2008; Ladeiro et al., 2008; Varnholt et al., 2008) .
Given the important role of miR-122 in liver pathology, we aimed (i) to evaluate the diagnostic and prognostic significance of miR-122 expression in human HCC, and (ii) to determine the functional implication of miR-122 deregulation in liver cancer development. By investigating the expression of miR-122 in 64 human HCC and 28 matched nonneoplastic surrounding liver tissues, we show that miR-122 repression in HCC correlates with clinically relevant parameters, such as etiology, survival, tumor size and differentiation status. Furthermore, we show that the loss of miR-122 expression correlates with distinct gene expression profiles characteristic of tumor progression (that is, suppression of hepatic differentiation phenotype and gain of metastatic properties). Finally, we identify liverenriched transcription factors as central functional regulators in the gene networks associated with the loss of miR-122 in human liver cancer and show that miR-122 is an important factor in the control of cellular migration and invasion.
Results
Heterogeneous expression of miR-122 in human HCC-derived cell lines Natural properties of miRNAs, including their small size and the lack of polyadenylated tail, have made their quantification challenging. Here, the expression of miR-122 was first determined by real-time quantitative reverse transcription-PCR in 21 HCC-derived cell lines (Lee and Thorgeirsson, 2002) using specific sets of primers ( Figure 1 and Supplementary Figure 1) . Interestingly, the levels of miR-122 were extremely variable with more than 1000-fold expression differences among the HCC cell lines. Some cell lines including PLC/PRF/5, Huh-1 and Hep40 showed very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (for example, SNU387 and SNU398). Specificity and reproducibility of PCR assays were confirmed by modulating the expression of miR-122 in vitro (Supplementary Figure 2) . We conclude that quantitative reverse transcription-PCR is a reliable assay for quantification of the miR-122 expression and that HCC cell lines represent a suitable model for functional studies of miR-122 in liver cancer.
Loss of miR-122 expression in HCC is associated with poor prognosis Next, the expression of miR-122 was analysed in a panel of 64 primary liver tumors and 28 matched nontumor surrounding liver tissues extensively characterized in our laboratory earlier (Lee et al., 2004a (Lee et al., , 2004b Kaposi-Novak et al., 2006; Coulouarn et al., 2008) . HCC samples were representative of patients with various clinical outcomes and pathological features (Table 1) . Interestingly, miR-122 levels were highly variable among the clinical samples (CV>2), suggesting that miR-122 expression in primary tumors was as heterogeneous as that found in cell lines.
To further explore clinical relevance, the expression of miR-122 was analysed as a function of various clinical parameters and tumor features (Figure 2) . First, the expression levels of miR-122 were compared between HCC subtypes characterized earlier by the experimentally well-defined gene expression signatures (Lee et al., 2004a (Lee et al., , b, 2006 Kaposi-Novak et al., 2006; Coulouarn et al., 2008) . As shown in Figure 2a , miR-122 was specifically repressed in the tumors that showed a bad prognosis signature. Accordingly, the overall survival time of the patients with low and high miR-122 expression in HCC was 30.3±8.0 and 83.7±10.3 months, respectively (Po0.001). MiR-122 was also repressed in a subset of HCC, which harbored a hepatoblast signature as well as a c-Met and a late (Figure 2a) . The hepatoblast signature, derived from hepatic progenitor cells, is specific for tumors with a poor differentiation status , whereas c-Met and late transforming growth factor-b signatures are associated with subsets of tumors with poor prognosis and aggressive phenotype Coulouarn et al., 2008) . The loss of miR-122 expression was correlated with a high proliferation and ubiquitination index along with a low apoptotic index (Figure 2b ). Supporting a recent observation (Varnholt et al., 2008) , the expression of miR-122 was clearly etiology-dependent as miR-122 was repressed only in HCC arising in HBV-infected livers (Figure 2c) . No significant correlations (Po0.05) were observed between the status of HBV infection and the presence of hepatoblast, transforming growth factor-b or c-Met signatures. Finally, miR-122 repression was found to be associated with poor differentiation status and large tumor size (Figure 2c ). Taken together, these data show that miR-122 expression in human HCC correlates with clinically relevant parameters and that the loss of miR-122 is a marker of poor prognosis.
miR-122 levels define specific gene expression profiles in HCC To get insights into the functional significance of miR-122 expression, tumors were divided into two groups. High and low miR-122-expressing tumors (15 and 17 cases, respectively) were defined by >2-fold changes in the median miR-122 expression across the samples. Gene expression profiling identified 509 nonredundant genes that were differentially expressed between the tumors with high versus low miR-122 expression (Supplementary Table 1 ). As expected, clustering analysis divided HCC into two distinct clusters (C1 and C2) defined by the level of miR-122 (Figure 3a) . Differentially expressed genes were similarly organized in two clusters and included genes that displayed either positive (cluster A) or negative (cluster B) correlation with miR-122 expression (Figure 3a) . Supporting our approach, cluster B included numerous predicted targets for miR-122 (for example, ALDOA, CLIC1 and RHOA). The specific contribution of miR-122 to the HCC transcriptome was further validated by testing the enrichment of the genes embedded in clusters A and B in the gene expression profiles derived from the experimental modulation of miR-122 levels (Krutzfeldt et al., 2005) . As shown in Figure 3b , genes highly expressed in clusters A and B (high and low miR-122 expressing HCC) were significantly enriched in the gene expression profiles corresponding to either control or mice treated with antagomir-122, respectively (Krutzfeldt et al., 2005) . In addition, the restoration of miR-122 expression in vitro to a large extent was able to shift the expression patterns of cluster A and B genes from C2 (Low miR-122) toward C1 (High miR-122) (Supplementary Figure 3 ). These results show that the expression of genes embedded in clusters A and B is highly dependent on miR-122 expression.
Loss of miR-122 in HCC coincides with suppression of the hepatic phenotype As shown in Figure 3a , the gene expression profiles were remarkably homogeneous within each subgroup of (Lee et al., 2004a Kaposi-Novak et al., 2006; Coulouarn et al., 2008) .
miR-122 repression is a marker of tumor progression in HCC C Coulouarn et al HCC, suggesting that miR-122 deregulation represents an important event during the course of HCC progression. To reveal the dominant signaling networks associated with the loss of miR-122 expression in HCC, systematic pathway and gene ontology analyses were performed using genes that either positively (cluster A) or negatively (cluster B) correlated with miR-122 expression. Ingenuity pathway analysis showed a clear relationship between the miR-122 associated gene expression signature and the functional categories linked to liver cancer and liver metabolism (Table 2) . Genes embedded in cluster A were implicated in molecular and cellular functions characteristic of welldifferentiated hepatocytes (Table 2 and Supplementary  Table 1 ). These genes were involved in lipid metabolism (APO-A1, -C4, -F), acute phase response (ITIH3, SERPIN-C1, -F2), detoxification (CYP-2C9, -3A4, 4A11) and coagulation (F12, F13B). Moreover, high expression of miR-122 correlated significantly with the global activation of an extensive regulatory network centered on HNF4A ( Figure 4a ). Enrichment of HNF4A targets among miR-122-positive HCC suggests the involvement of miR-122 in maintaining hepatocyte differentiation, thereby implying that the loss of miR-122 contributes to suppression of the hepatic phenotype in HCC with poor prognosis (Figure 2 ).
Relationship between miR-122 and liver-enriched transcription factors As a paradigm, HCC-derived cell lines were divided into two groups based on the miR-122 expression levels. Gene expression profiling identified 300 genes that were differentially expressed as a function of miR-122 expression (Supplementary Figure 4) . Consistent with our findings in primary tumors, high levels of miR-122 in HCC-derived cell lines were correlated with high expression of genes involved in the pathways character- Table 2 ). These included genes encoding apolipoproteins (APO-A1), coagulation factors (F2) and acute phase proteins (AHSG). More importantly, miR-122 showed a strong positive correlation with the expression level of numerous liver-enriched transcription factors essential for hepatocytic differentiation, such as HNF1A, HNF3A, HNF3B, HNF4A, HNF4G and HNF6 (Supplementary Figure 5) . Gene network analysis not only confirmed activation of the HNF4A signature in HCC-derived cell lines expressing miR-122 but also revealed strong interactions with other liver-enriched transcription factors (Figure 4b ). In this context, HNF4A was directly evaluated as a function of miR-122 expression. As shown in Figures 4c-e, HNF4A expression was directly correlated with the expression of miR-122, both on the mRNA and protein levels. Furthermore, in the high miR-122 expressing cell lines, HNF4A was particularly enriched in the nuclear fraction compared with the cytoplasmic fraction, reflecting its greater transcriptional activity (Figure 4e ). The latter is consistent with a central role of HNF4 revealed by the network analysis in the miR-122 overexpressing HCC cell lines (Figure 4b ). Despite a strong positive correlation, the exact relationship between miR-122 and HNF4A appears to be highly complex. The lack of miR-122 seed region in the 3 0 UTR of HNF4A transcript makes HNF4A an unlikely direct target of miR-122. Accordingly, the experimental modulation of miR-122 expression did not affect HNF4A mRNA and protein levels (data not show). It is also dubious whether HNF4A directly drives the expression of miR-122, as the silencing of HNF4A by small interfering RNA did not significantly change the expression of miR-122 ( Figure 5) . Conversely, the knockdown of HNF1A, HNF3A or HNF3B was able to reduce miR-122 expression, implying that mir-122 may be under the transcriptional control of these transcription factors ( Figure 5 ). These results provide new insight into the transcriptional regulation of the miR-122 gene and implicate miR-122 as a marker of hepatocyte differentiation. Loss of miR-122 coincides with acquisition of invasive phenotype Lastly, we analysed the genes that were negatively correlated with miR-122 (cluster B in Figure 3a) . Expression profiling indicated that the loss of miR-122 expression was associated with a higher expression of numerous genes related to metastasis, including genes involved in cell motility (RAC1, RHOA), angiogenesis (VEGF), hypoxia (HIF1A) and epithelial-mesenchymal transition (vimentin) (Supplementary Table 1 , Supplementary Figure 6 ). It is noted that RHOA and RAC1 were two central molecules in a network associated with cell motility (Figure 6a ). Therefore, we investigated the impact of miR-122 loss on cell motility. As shown in Figure 6b , the experimental inhibition of miR-122 in Huh-1 cells resulted in an increase of migration and invasion. Furthermore, by validating the importance of miR-122 in the control of cell motility, the ectopic expression of miR-122 was able to reduce the migration and invasion of SK-Hep1 cells (Figure 6c ). These data emphasize the critical role of the loss of miR-122 expression during tumor progression and the potential relevance of miR-122 restoration for HCC therapy.
Discussion
Accumulating evidence suggests a causal role for miRNAs in human cancer (Esquela-Kerscher and Slack, 2006) . In this study, we have evaluated the clinical and functional relevance of liver-specific miR-122 for human HCC. We show that the repression of miR-122 correlates with clinically relevant parameters, such as etiology, tumor size and differentiation grade. More importantly, miR-122 repression is specific for liver tumors, which are characterized by poor prognosis, and coincides with suppression of hepatic phenotype as well as gain of metastatic properties. Our findings show a link between the expression levels of miR-122 and HBV or HCV infection. By analysing the expression of miR-122 in a cohort of HCC with miR-122 repression is a marker of tumor progression in HCC C Coulouarn et al different etiology, we have established that the downregulation of miR-122 occurs mainly in the HCC arising in the HBV-infected livers. In the HCC developed with HCV infection, miR-122 expression was either maintained or increased, in agreement with recent observations (Varnholt et al., 2008) . Interestingly, the efficiency of HCV replication has been found to be closely correlated with the miR-122 expression levels (Jopling et al., 2005; Chang et al., 2008) , and further studies have implicated miR-122 in HCV translation, suggesting the involvement of miR-122 in HCV tropism to the liver (Henke et al., 2008) . Therefore, we speculate that HCV not only requires the host-expressed miR-122 for its replication, but also it may either directly induce miR-122 expression or indirectly inhibit miR-122 downregulation.
Similar to the transcription factors, tissue specificity of miRNA expression may imply a role in differentiation. Owing to its high abundance in the liver, it has HNF4A HNF3B Figure 5 The silencing of HNF1A, HNF3A and HNF3B results in a decrease of miR-122 level. The high miR-122 expressing PLC/PRF/5 cell line was transfected with 40 nM of specific small interfering RNA (siRNA) directed against HNF-1A, -3A, -3B and -4A (siRNA, black column) versus negative control (NC, white column). Forty-eight hours after the transfection, the efficiency of the silencing was confirmed by the decreased level of the respective mRNA (upper panel). As shown in the lower panel, the silencing of HNF-1A, -3A and -3B significantly reduces the level of miR-122. miR-122 repression is a marker of tumor progression in HCC C Coulouarn et al been suggested that miR-122 may maintain the hepatic differentiation status by repressing the genes that are normally not expressed by hepatocytes (Girard et al., 2008) . The temporal expression pattern of miR-122 during liver development is consistent with its involvement in liver differentiation (Chang et al., 2004) . In support of this notion, recent work showed that the promotion of endodermal differentiation of human embryonic stem cells by NaButyrate was associated with an increase of miR-122 expression and a parallel activation of several hepatocyte-specific genes (Tzur et al., 2008) . According to our findings in human HCC and HCC-derived cell lines, the expression of miR-122 was tightly correlated with the expression of numerous genes characteristic of the differentiated hepatocytes.
In agreement with the current view of miR-122 as a regulator of lipid and cholesterol metabolism, the expression of abundant apolipoprotein genes was found to be correlated with miR-122 levels (Krutzfeldt et al., 2005; Esau et al., 2006; Elmen et al., 2008) . The specific downregulation of miR-122 in poorly differentiated tumors as well as in tumors characterized by the hepatoblast gene signature supported miR-122 as an important determinant of hepatic differentiation. Moreover, in two independent data sets, we identified HNF4A as the central regulatory transcription factor in the network of genes that were differentially expressed as a function of miR-122 expression. HNF4A is a liver-enriched transcription factor controlling the differentiation-dependent gene expression in developing and adult livers (Odom et al., 2004) . Although we initially speculated that HNF4A was the missing link between the differentiation status and the transcription of miR-122 gene, the additional gene-silencing experiments suggested a more important role for other liver-enriched transcription factors, such as HNF1A, HNF3A and HNF3B. The promoter region of miR-122 gene has not been yet identified but a binding site for HNF3B has been located 5 kb upstream of miR-122 (Supplementary Figure 7) . Although further experiments are needed to address the functionality of this binding site, our data provide the first evidence for the tissue specificity of miR-122 expression. Using a comparative genomic approach based on the experimentally well defined gene expression signatures, we have identified earlier several clinically relevant subtypes of HCC with significant differences in the biological properties and clinical outcome (Lee et al., 2004a (Lee et al., , b, 2006 Kaposi-Novak et al., 2006; Coulouarn et al., 2008) . Importantly, we showed here that the repression of miR-122 was characteristic of HCC, which displayed a hepatoblast, c-Met or late transforming growth factor-b signature. These HCC subtypes were characterized by increased invasiveness, tumor recurrence and decreased patient survival whereby raising a possibility that the loss of miR-122 may predispose to the acquisition of invasive phenotype. Consistent with this, miR-122 was recently described as a metastasisrelated miRNA in HCC (Budhu et al., 2008) , and repression of miR-122 was reported in highly metastatic human breast cancer cell lines (Tavazoie et al., 2008) .
Supporting these data, our results show that HCC cell lines known to exhibit a more invasive phenotype also displayed a decreased miR-122 expression (Coulouarn et al., 2008) . In addition, a significant enrichment of genes related to metastasis (RHOA, VEGF, HIF1A, Vimentin) was observed both in HCC and cell lines lacking miR-122 expression (Supplementary Table 1 ). Accordingly, we provide direct evidence that the modulation of miR-122 greatly influenced the propensity of cancer cells to migrate and invade. Indeed, the loss of miR-122 resulted in the acquisition of migrating and invasive properties and the restoration of miR-122 was able to reverse this phenotype. In an attempt to identify the underlying molecular mechanisms responsible for the impact of miR-122 on cell motility, we used miRNA target prediction algorithms on genes negatively correlated with miR-122. Interestingly, an evolutionary conserved binding site for miR-122 was detected in the 3 0 UTR of RHOA mRNA (Supplementary Figure 8a) , and the analysis of the secondary structure of RHOA 3 0 UTR indicated that the predicted binding site coincided with a hairpinloop structure, making this sequence probably accessible for an interaction with miR-122 (Supplementary Figure 8b) . RHOA is frequently overexpressed in HCC and several groups correlated the increase of RHOA expression with tumor progression, cell differentiation and metastasis (reviewed by Grise et al., 2009) . Moreover, RHOA overexpression in liver has been directly correlated with the acquisition of an aggressive phenotype, both in vitro and in vivo (Yoshioka et al., 1995; Xue et al., 2008) . In addition, gene reporter experiments suggested a direct functional interaction between miR-122 and RHOA 3 0 UTR (Supplementary Figure 8c) . Nevertheless, the experimental inhibition or induction of miR-122 failed to show a consistent modulation of RHOA on a protein level. Also, the acquisition of invasive properties observed on miR-122 inhibition (Figure 6b ) appeared to be independent of RHOA, as the silencing of RHOA did not significantly abrogate this response. The absence of RHOA modulation on a protein level could be due to an enhanced stability of the protein. Alternatively, RHOA transcript may be tightly regulated by positive and negative signals. For example, the increase in the oncogenic miR-155, which was recently reported to target and reduce the level of RHOA (Kong et al., 2008) , may counteract the miR-122 effect. These observations raise important questions regarding the regulation of transcript stability by miRNAs and suggest that the integration of activating and inhibitory signals driven by different miRNAs may define the level of a particular transcript. Interestingly, while writing this paper, Tsai et al. (2009) published that miR-122 regulates intrahepatic metastasis by controlling the disintegrin and metalloprotease ADAM17. Together, these data not only emphasize the critical role of miR-122 in migration and invasion but also suggest that miR-122 contribution to tissue remodeling is broader than a direct effect on actin cytoskeleton organization through a RHOA-dependent mechanism.
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In conclusion, our work sheds new light on the clinical and functional implications of miR-122 expression in liver cancer. We identified miR-122 as a new diagnostic and prognostic miRNA marker for HCC progression. Given that the modulation of miR-122 expression became a reality in animal models (Czech, 2006; Elmen et al., 2008) , our study provides a rationale for the classification and development of novel therapy for human HCC.
Materials and methods
Human tissue samples A total of 64 HCC tissues and 28 matched nontumor surrounding liver tissues were obtained from patients undergoing partial hepatectomy as treatment for HCC. Tissue banking was approved by the Institutional Review Board of the US National Cancer Institute. The determination of proliferation, apoptosis and ubiquitination index was described earlier (Lee et al., 2004b) . Total RNAs were isolated using the CsCl density gradient centrifugation method .
Cell lines
HCC-derived cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and RIKEN Cell Bank (Ibaraki, Japan) and maintained in Dulbecco's modified Eagle's medium/F12 medium supplemented with 2 mM glutamine and 10% fetal bovine serum, as described (Lee and Thorgeirsson, 2002) . Total RNAs were extracted from cells at 80% confluence using the RNeasy mini kit (Qiagen, Valencia, CA, USA).
Cell transfection
Transfections were carried out using siPORT NeoFX according to the manufacturer's instructions (Ambion, Austin, TX, USA). RNA and protein analysis were conducted after 48 h incubation in normal culture condition. miRIDIAN miRNA Hairpin Inhibitors and Mimics from Dharmacon (Waltham, MA, USA) were used for the specific inhibition and overexpression of miR-122. The amount of small RNA was adjusted to a final concentration of 20 nM. The efficiency and specificity of the transfections were evaluated by confocal microscopy and quantitative reverse transcription-PCR (Supplementary Figure 9 ). Silencer select small interfering RNAs along with the negative control no. 1 (Ambion) were used for the specific knockdown of HNF1A (s13870), HNF3A (s6689), HNF3B (s6692), HNF4A (s6698), FOXO1 (s5259) and RHOA (s760).
Real-time reverse transcription-PCR of miR-122
Expression of miR-122 was measured using the mirVana quantitative reverse transcription-PCR miRNA Detection Kit and SYBR Green I (Ambion). Total RNA was reverse transcribed at 37 1C for 30 min with an ArrayScript Enzyme mix including miR-122 specific RT primers according to the manufacturer's instructions. Quantitative PCR analysis was performed with an IQ-5 real-time PCR detection system (BioRad Laboratories, Hercules, CA, USA) in a 96-well reaction plate. Melting analysis of the PCR products was conducted to validate the amplification of the specific product. Quantitative values were determined using the 2 ÀDDCt method, where the DC t value of a given RNA sample was calculated by subtracting the C t value of miR-122 from the C t value of 5S small RNA used for normalization.
DNA microarray analysis
The gene expression data used in this study (GEO accession numbers: Human microarray platform, GPL1528; human HCC microarray data, GSE1898) were generated using a genome-wide set of long-mer human oligonucleotides obtained from Illumina (San Diego, CA, USA) and printed at the Advanced Technology Center (National Cancer Institute). Target preparation and hybridization on microarrays were described earlier (Lee and Thorgeirsson, 2002) . Differentially expressed genes were identified by a univariate two-sample t-test with a random variance model. Permutation P-values for significant genes (Po0.01) were computed on the basis of 10 000 random permutations as described earlier . Expression profiles were clustered by the Cluster 3.0 program (http//rana.lbl.gov/EisenSoftware. html) using an unsupervised hierarchical procedure and visualized with the TreeView program (http//rana.lbl.gov/ EisenSoftware.html) .
Gene set enrichment analysis and pathway analysis Gene set enrichment analysis was performed using the webbased tool developed by Broad Institute (www.broad.mit.edu/ gsea/). Enrichment scores were determined after 1000 permutations. The Ingenuity pathway analysis tool was used to examine the functional associations between differentially expressed genes and to generate the highest significant gene networks (www.ingenuity.com). Biologically relevant networks were identified using the scoring system provided by Ingenuity (Mountain View, CA, USA).
miRNA target prediction Potential miR-122 target among genes negatively correlated with miR-122 expression was determined using the publicly available miRanda (www.microrna.org) and TargetScan (www.targetscan.org) algorithms. The secondary structure of potential target transcripts was explored using the web-based RNA analyser tool (www.wb2x01.biozentrum. uni-wuerzburg.de).
RHOA 3
0 UTR reporter analysis The human sequence of the RHOA 3 0 UTR was amplified by PCR using Phusion high-fidelity DNA polymerase (New England Biolabs, Ipswich, MA, USA) and cloned into a SacI-and HindIII-cut pMIR-Report luciferase vector (Ambion). A mutant construct was generated by introducing mutations in the putative miR-122-binding site. Mutations were introduced by stand overlap PCR using mutagenic primers. All constructs were sequenced to confirm that the desired mutations had been obtained. Firefly luciferase constructs containing the wildtype or the mutant variant of RHOA 3 0 UTR were co-transfected with a b-galactosidase control vector in the presence of 20 nM miR-122 inhibitor or negative control. Transfections were performed with 0.1 mg firefly luciferase constructs and 0.01 mg b-galactosidase normalization vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Luciferase and b-galactosidase activities were assessed 48 h after transfection using a dual-light chemiluminescent reporter gene assay system (Applied Biosystems, Foster City, CA, USA).
Invasion and migration assays
The effect of miR-122 on invasion and migration was evaluated by using the BD BioCoat Matrigel Invasion Chambers (San Jose, CA, USA) as described (Coulouarn et al., 2008) . Immunoblotting Protein expression analysis was as described earlier . Protein extraction was performed using M-PER and NE-PER reagents (Pierce, Rockford, IL, USA). Twenty micrograms of protein extract were subjected to SDSpolyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. Membranes were probed with a goat polyclonal HNF4A antibody and a rabbit polyclonal RHOA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Detection was performed by ECL (Amersham Biosciences, Piscataway, NJ, USA) after incubation of an horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology).
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